Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 708 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is M  [Clear All Filters]
2021
Brouwer PJM, Antanasijevic A, de Gast M, Allen JD, Bijl TPL, Yasmeen A, Ravichandran R, Burger JA, Ozorowski G, Torres JL et al..  2021.  Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.. NPJ Vaccines. 6(1):24.
Brouwer PJM, Antanasijevic A, de Gast M, Allen JD, Bijl TPL, Yasmeen A, Ravichandran R, Burger JA, Ozorowski G, Torres JL et al..  2021.  Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.. NPJ Vaccines. 6(1):24.
Klasse PJ, Nixon DF, Moore JP.  2021.  Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.. Sci Adv. 7(12)
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..  2021.  Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..  2021.  Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..  2021.  Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Black KA, Duan L, Mandyoli L, Selbach BP, Xu W, Ehrt S, Sacchettini JC, Rhee KY.  2021.  Metabolic bifunctionality of Rv0812 couples folate and peptidoglycan biosynthesis in Mycobacterium tuberculosis.. J Exp Med. 218(7)
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..  2021.  Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..  2021.  Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..  2021.  Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..  2021.  Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..  2021.  Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Chen X, Lee SKoo, Song M, Zhang T, Han MShin, Chen Y-T, Chen Z, Ma X, Tung C-H, Du Y-CNancy.  2021.  RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. Mol Ther Oncolytics. 23:277-287.
Ngwa CJ, Gross MR, Musabyimana J-P, Pradel G, Deitsch KW.  2021.  The Role of the Histone Methyltransferase PfSET10 in Antigenic Variation by Malaria Parasites: a Cautionary Tale.. mSphere. 6(1)
Moore JP, Offit PA.  2021.  SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.. JAMA. 325(9):821-822.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..  2021.  Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..  2021.  Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.